Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference

Core Insights - Ribo Life Science has been invited to present at the RNA Leaders Europe Conference, highlighting its advancements in ex-hepatic delivery technologies [1] - The company has achieved significant success with its RiboGalSTAR™ platform, which targets liver-specific genes and has secured collaborations and licensing deals valued over USD 6 billion [1] - Ribo is now focusing on expanding its proprietary RiboPepSTAR™ delivery technology to enable targeted siRNA delivery to organs beyond the liver, including the kidneys, heart, adipose tissue, muscle, and central nervous system [1] Group 1 - Ribo Life Science will present data on ex-hepatic delivery at the RNA Leaders Europe Conference in Vienna on March 19, 2026 [1] - The company has seven clinical programs and two major global collaborations, indicating a strong pipeline and strategic partnerships [1] - The RiboPepSTAR™ platform has demonstrated effective kidney delivery with preclinical data showing specific uptake and mRNA knockdown across species [1] Group 2 - Ribo is developing additional targeted drug candidates to extend therapeutic applications to various diseases beyond liver conditions [1] - The company aims to advance its ex-liver product offerings to provide innovative siRNA therapeutics to patients globally [1]